A Pilot Study of 89Zr-girentuximab for PET Imaging in Residual or Recurrent Post Ablative Tumors in Patients With Renal Cell Carcinoma.
Massachusetts General Hospital
Summary
The goal of this clinical trial is to learn whether 89Zr-Girentuximab PET scans can inform management of renal cell carcinoma. The main questions it aims to answer are: * Does the 89Zr-Girentuximab PET detect ccRCC that is left behind or has come back after treatment? * What differences can be seen on the 89Zr-Girentuximab PET before and after standard of care treatment? Participants in arm 1 will be given the study drug followed by a PET scan 3-7 days after injection. Participants in arm 2 will receive the same, but will proceed with their standard of care cryoablation after the initial PET scan. Within 3 days of the cryoablation treatment, participants will receive a repeat PET scan.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Written and voluntarily given Informed Consent 2. ≥18 years of age at time of consent a. Because no dosing or adverse event data are currently available on the use of 89Zr-girentuximab in participants \<18 years of age, children are excluded from this study, but will be eligible for future pediatric trials. 3. Have the capacity to understand the study and be willing and able to comply with all protocol requirements. 4. Findings suspicious for post-ablation residual or recurrent ccRCC (subjects in cohort 1) documented at conventional imaging or biopsy, performed with…
Interventions
- Drug89Zr-Girentuximab
89Zr-Girentuximab PET
Location
- Massachusetts General HospitalBoston, Massachusetts